European business strategy – grow faster than the market
Daiichi Sankyo intends to carry out its growth strategy in Europe and to increase net sales to €1.2 billion by 2012. The main growth driver to achieve this ambitious goal will be the company's business portfolio. To expand its European sales, Daiichi Sankyo is also entering new markets and, as a result, extending its geographical reach.
In 2008, new affiliates were opened in Turkey, the fastest growing pharmaceutical market in the region, and in Ireland. New market entries are now being considered in Scandinavia and eastern Europe.
Daiichi Sankyo Europe also aims to increase its presence in its traditional markets. In 2008 and 2009, the company invested in its internal resources and substantially extended its field-force capacities in different countries. Growth rates of about a 50 per cent in staffing levels have been achieved in Germany, Italy and Spain. In France, the workforce was even doubled.
Acquisitions and in-licensing activities as well as marketing and licensing agreements with other pharmaceutical companies round up the approaches Daiichi Sankyo will take to enhance its presence in Europe.